A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author of a new paper published in Signal Transduction and Targeted Therapy, "AAV ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The Food and Drug Administration will request that the company ...
A retired HGV driver was the first person in the world to take part in a clinical trial to extend the lifespan of blood ...
A new treatment might just be hope for many people living with chronic pain. In a recent preclinical study, researchers ...
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback